Anthony P Adamis insider trades: Eyetech Pharmaceuticals (EYET) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Anthony reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 3, 2005 | EYET | ↓ Sell | 106,094 | $17.68 | $1.9M | Direct | Nov 7, 2005 (4d) |
| Aug 1, 2005 | EYET | ↓ Sell10b5-1 | 5,325 | $11.35 | $60K | Direct | Aug 1, 2005 (0d) |
| Jul 1, 2005 | EYET | ↓ Sell10b5-1 | 5,325 | $12.59 | $67K | Direct | Jul 1, 2005 (0d) |
| Jun 1, 2005 | EYET | ↓ Sell10b5-1 | 5,325 | $12.95 | $69K | Direct | Jun 3, 2005 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Anthony P Adamis's insider trades
Anthony P Adamis is Chief Scientific Officer at Eyetech Pharmaceuticals (EYET). Since Jun 1, 2005, Anthony has reported no open-market purchases and 4 sales worth $2.1M on SEC Form 4. There have been no open-market trades in the last 12 months.
3 sales (9% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (7 filings), option exercises (3 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every EYET insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.